Chloe Ramirez
The Ebola V920 vaccine, also known as rVSV-ZEBOV, is a recombinant vesicular stomatitis virus-based vaccine designed to protect against the Zaire ebolavirus species, which is responsible for the most deadly Ebola outbreaks. Developed by Merck & Co., the vaccine utilizes a genetically modified version of the vesicular stomatitis virus, where one of its genes is replaced with the Ebola virus glycoprotein gene, enabling the immune system to recognize and combat the Ebola virus without causing the disease itself. This single-dose vaccine has shown high efficacy in clinical trials, including the landmark ring vaccination strategy during the 2014-2016 West African Ebola outbreak, and was approved by the U.S. Food and Drug Administration (FDA) in 2019, marking a significant milestone in the fight against this deadly disease.
| Characteristics | Values |
|---|---|
| Type of Vaccine | Recombinant Vesicular Stomatitis Virus (rVSV) vaccine |
| Target Pathogen | Ebola Virus (specifically Zaire ebolavirus species) |
| Manufacturer | Developed by Merck & Co. (originally by NewLink Genetics and Public Health Agency of Canada) |
| Vaccine Name | rVSV-ZEBOV (also known as Ervebo or Ebola V920) |
| Administration Route | Intramuscular injection |
| Dosage | Single dose (0.5 mL) |
| Storage Temperature | -60°C to -80°C (ultra-low temperature for long-term storage) |
| Shelf Life | Up to 2 years under recommended storage conditions |
| Efficacy | Approximately 97.5% effective in preventing Ebola virus disease |
| Approval Status | Approved by the FDA (2019), EMA (2019), and WHO prequalified (2019) |
| Use in Outbreaks | Deployed in Ebola outbreaks in Democratic Republic of Congo (DRC) |
| Side Effects | Common: headache, fatigue, muscle pain, fever; rare: severe allergic reactions |
| Population Approved For | Adults aged 18 years and older |
| Technology Platform | Recombinant viral vector (VSV virus expressing Ebola glycoprotein) |
| Development Timeline | Accelerated development during the 2014-2016 West Africa Ebola outbreak |
| Global Access | Included in the WHO’s Emergency Use Listing (EUL) for outbreak response |
Explore related products
What You'll Learn
- V920's Vaccine Type: V920 is a recombinant vesicular stomatitis virus-based Ebola vaccine candidate
- Development History: Developed by Merck, V920 emerged from research on rVSV-ZEBOV technology
- Mechanism of Action: It uses a weakened VSV virus to deliver Ebola glycoprotein, triggering immunity
- Clinical Trials: Phase 1-3 trials showed high efficacy in preventing Ebola virus disease
- Approval Status: V920 (Ervebo) is approved by WHO and several countries for Ebola prevention
V920's Vaccine Type: V920 is a recombinant vesicular stomatitis virus-based Ebola vaccine candidate
The V920 Ebola vaccine, also known as rVSV-ZEBOV, is a groundbreaking recombinant vaccine designed to combat the Zaire ebolavirus, the most lethal strain of Ebola. Unlike traditional vaccines that use weakened or inactivated forms of the virus, V920 employs a clever genetic engineering approach. It utilizes the vesicular stomatitis virus (VSV), a virus that primarily affects livestock, as a backbone. Scientists replace a key gene in VSV with the gene coding for the Ebola virus's surface protein, known as the glycoprotein. This glycoprotein is crucial for Ebola's ability to enter and infect human cells.
When administered, the modified VSV delivers the Ebola glycoprotein into the body, triggering a robust immune response. The immune system recognizes the foreign glycoprotein and generates antibodies specifically targeting it. These antibodies act as sentinels, ready to neutralize the real Ebola virus if exposure occurs.
This recombinant approach offers several advantages. Firstly, it eliminates the risk of the vaccine causing Ebola disease itself, as it doesn't contain the complete Ebola virus. Secondly, VSV is known to induce strong immune responses, potentially leading to a more effective vaccine. Clinical trials have shown promising results, with V920 demonstrating high efficacy in preventing Ebola infection.
The recommended dosage for V920 is a single intramuscular injection of 2 x 10^7 plaque-forming units (PFU). This dosage has been shown to be safe and effective in clinical trials involving adults aged 18 and above. It's important to note that V920 is currently approved for use in adults only, and further research is needed to determine its safety and efficacy in children.
While V920 represents a significant advancement in Ebola prevention, it's crucial to remember that vaccination is just one tool in the fight against this deadly disease. Public health measures like contact tracing, isolation, and community engagement remain vital for controlling outbreaks. Additionally, ongoing research is exploring the potential of V920 for post-exposure prophylaxis, offering a glimmer of hope for those exposed to the virus before symptoms appear.
Hepatitis B Vaccine: Who Pays for Protection?
You may want to see also
Explore related products
Development History: Developed by Merck, V920 emerged from research on rVSV-ZEBOV technology
The Ebola V920 vaccine, developed by Merck, is a recombinant vesicular stomatitis virus (rVSV) vector-based vaccine. Its development history is deeply rooted in the innovative rVSV-ZEBOV technology, which leverages a weakened version of the vesicular stomatitis virus to deliver a key protein from the Ebola virus, triggering an immune response. This approach emerged as a breakthrough in vaccine science, offering a rapid and effective solution to combat one of the deadliest pathogens known to humanity.
The journey of V920 began with the urgent need to address the 2014–2016 Ebola outbreak in West Africa, which claimed over 11,000 lives. Merck, in collaboration with NewLink Genetics and the Public Health Agency of Canada, accelerated research on the rVSV-ZEBOV platform. This technology had shown promise in preclinical studies, but the outbreak catalyzed its transition to human trials. Phase 1 trials in 2014 demonstrated safety and immunogenicity, paving the way for larger studies. By 2015, a ring vaccination trial in Guinea revealed an efficacy rate of 100%, a landmark achievement in vaccine development.
One of the key advantages of the rVSV-ZEBOV technology is its single-dose regimen, which simplifies administration in resource-limited settings. Unlike traditional vaccines requiring multiple doses, V920 provides robust immunity with just 1 mL administered intramuscularly. This efficiency was critical during the outbreak, where rapid deployment and ease of use were paramount. The vaccine is approved for individuals aged 18 and older, though studies are ongoing to evaluate its safety in younger populations.
Merck’s commitment to accessibility is evident in its partnership with Gavi, the Vaccine Alliance, to ensure V920’s availability in low-income countries. Prequalification by the World Health Organization (WHO) in 2019 further solidified its global reach. However, challenges remain, including cold chain requirements (storage between 2°C and 8°C) and potential side effects such as headache, fatigue, and muscle pain. Healthcare providers must monitor recipients for rare adverse reactions, such as arthralgia or transient fever, which typically resolve within 48 hours.
In conclusion, V920’s development history exemplifies how cutting-edge science, coupled with global collaboration, can transform a research concept into a life-saving tool. Its rVSV-ZEBOV foundation not only revolutionized Ebola prevention but also set a precedent for rapid vaccine development against emerging pathogens. For practitioners, understanding its single-dose protocol, storage needs, and side effect profile is essential for effective deployment in outbreak scenarios.
Vaccine Myth: Cancer Risk or Cancer Prevention?
You may want to see also
Mechanism of Action: It uses a weakened VSV virus to deliver Ebola glycoprotein, triggering immunity
The Ebola V920 vaccine, also known as rVSV-ZEBOV, is a groundbreaking example of viral vector technology in action. Its mechanism hinges on a clever manipulation of the immune system. Imagine a Trojan horse, but instead of soldiers, it carries a harmless fragment of the Ebola virus. This "horse" is a weakened vesicular stomatitis virus (VSV), chosen for its ability to infect cells efficiently without causing disease in humans.
The VSV acts as a delivery system, ferrying a single Ebola protein, the glycoprotein, into the body. This glycoprotein is the key target for our immune system.
This glycoprotein, normally studding the surface of the Ebola virus, is the key to its deadly efficiency. It allows the virus to latch onto and invade our cells. In the vaccine, however, this glycoprotein is presented in isolation, devoid of the virus's harmful machinery. The immune system, ever vigilant, recognizes this foreign protein as a threat and mounts a robust response. It generates antibodies specifically tailored to neutralize the Ebola glycoprotein, effectively disarming the virus should a real infection occur.
Simultaneously, the immune system creates memory cells, a specialized force trained to recognize and swiftly eliminate the Ebola glycoprotein upon any future encounter. This dual action – immediate antibody production and long-term immune memory – is the cornerstone of the V920 vaccine's protective power.
The beauty of this approach lies in its elegance and safety. By using a weakened virus as a vector, the vaccine avoids the risks associated with live, attenuated Ebola virus vaccines. The VSV, though weakened, retains its ability to infect cells, ensuring efficient delivery of the Ebola glycoprotein. This targeted approach minimizes potential side effects while maximizing the immune response.
Importantly, the V920 vaccine is administered as a single dose, making it logistically feasible for mass vaccination campaigns in outbreak settings. Its efficacy has been demonstrated in clinical trials, offering a beacon of hope in the fight against this devastating disease.
Understanding the mechanism of the V920 vaccine highlights the ingenuity of modern vaccinology. By harnessing the power of a weakened virus as a delivery system, scientists have created a safe and effective weapon against Ebola. This technology holds promise not only for Ebola but also for the development of vaccines against other deadly pathogens, paving the way for a healthier future.
Vaccinating Your Child: Weighing Risks, Benefits, and Expert Advice
You may want to see also
Clinical Trials: Phase 1-3 trials showed high efficacy in preventing Ebola virus disease
The Ebola V920 vaccine, also known as rVSV-ZEBOV, is a recombinant vesicular stomatitis virus (VSV)-based vaccine designed to protect against the Zaire ebola virus species, the most lethal strain responsible for major outbreaks. Its development and clinical trials have been a cornerstone in the fight against Ebola virus disease (EVD), offering a beacon of hope in regions plagued by this devastating illness.
Clinical trials for Ebola V920 followed the standard three-phase process, each phase building upon the last to establish safety, immunogenicity, and efficacy. Phase 1 trials, conducted in healthy volunteers, primarily assessed the vaccine's safety profile and dosage. Researchers administered varying doses (ranging from 1x10^6 to 5x10^7 plaque-forming units) to determine the optimal amount that elicited a robust immune response without causing significant adverse effects. This phase confirmed the vaccine's tolerability, with mild to moderate side effects like headache, fatigue, and injection site pain being the most common.
Phase 2 trials expanded the study population to include individuals in Ebola-affected regions, focusing on immunogenicity and refining the dosage. These trials demonstrated that a single dose of 2x10^7 plaque-forming units consistently induced a strong immune response, characterized by the production of Ebola-specific antibodies and T-cell activation. This phase also explored the vaccine's efficacy in different age groups, revealing comparable immune responses in adults and adolescents, paving the way for broader application.
The pivotal Phase 3 trials employed a ring vaccination strategy, targeting contacts of confirmed Ebola cases and their contacts, creating a protective ring around each case. This approach not only tested the vaccine's efficacy in a real-world outbreak setting but also provided immediate protection to those at highest risk. Results were remarkable, showing a vaccine efficacy of approximately 97.5% in preventing Ebola virus disease, a testament to its potential as a powerful tool in outbreak control.
The success of these clinical trials has led to the approval and deployment of Ebola V920 in several countries, offering a critical intervention in the ongoing battle against Ebola. Its single-dose regimen and high efficacy make it a practical and effective solution, particularly in resource-limited settings where rapid response is crucial. However, continued monitoring and research are essential to understand long-term immunity and the vaccine's impact on different Ebola strains, ensuring its sustained effectiveness in the face of evolving viral threats.
Understanding the Unvaccinated: Who Can’t Receive Vaccines and Why
You may want to see also
Approval Status: V920 (Ervebo) is approved by WHO and several countries for Ebola prevention
The Ebola V920 vaccine, known commercially as Ervebo, is a recombinant vesicular stomatitis virus (rVSV) vaccine designed to protect against the Zaire ebolavirus species, the most lethal and prevalent strain responsible for major outbreaks. Its approval status is a testament to its efficacy and safety, marking a significant milestone in global health efforts to combat Ebola. The World Health Organization (WHO) granted prequalification to Ervebo in 2019, a critical step that allows for its procurement by United Nations agencies and Gavi, the Vaccine Alliance, ensuring widespread access in outbreak-prone regions. This approval was based on robust clinical trial data, including a ring vaccination trial in Guinea during the 2014–2016 West African outbreak, where it demonstrated approximately 97.5% efficacy in preventing Ebola virus disease.
Following WHO prequalification, several countries have independently approved Ervebo for use in their populations. The European Commission granted marketing authorization in 2019, making it the first Ebola vaccine approved in the European Union. The United States Food and Drug Administration (FDA) followed suit in December 2019, approving it for individuals aged 18 years and older. In Africa, the Democratic Republic of Congo (DRC) and other Ebola-affected nations have incorporated Ervebo into their public health strategies, particularly during outbreaks. The vaccine is administered as a single 1-milliliter intramuscular injection, preferably in the deltoid muscle, and has been shown to induce a rapid immune response, offering protection within 10 days of vaccination.
The approval of Ervebo is not just a regulatory milestone but a practical tool for outbreak response. During the 2018–2020 Ebola outbreak in the DRC, the vaccine was deployed under a compassionate use protocol, preventing an estimated 70% of cases in vaccinated individuals. Its approval has streamlined its use in ring vaccination strategies, where contacts and contacts of contacts of confirmed cases are vaccinated to create a protective barrier around the infection. This approach has been pivotal in containing outbreaks before they escalate into epidemics.
Despite its approval, challenges remain in ensuring equitable access and distribution. Cold chain requirements, as Ervebo must be stored between -60°C and -80°C, pose logistical hurdles in resource-limited settings. However, ongoing efforts to develop thermostable formulations and improve supply chain infrastructure aim to address these barriers. Additionally, public health campaigns are essential to combat vaccine hesitancy and ensure high uptake in at-risk communities.
In summary, the approval of V920 (Ervebo) by the WHO and multiple countries represents a triumph of scientific innovation and global collaboration. Its single-dose regimen, high efficacy, and proven impact in real-world settings make it a cornerstone of Ebola prevention strategies. As efforts continue to expand access and improve delivery, Ervebo stands as a critical tool in the fight against one of the world’s most feared diseases.
Best Cervical Cancer Vaccine: HPV Prevention and Protection Guide
You may want to see also
Frequently asked questions
The Ebola V920 vaccine is a recombinant vesicular stomatitis virus (rVSV) vaccine.
The Ebola V920 vaccine works by using a genetically modified version of the vesicular stomatitis virus (VSV) to express a glycoprotein from the Ebola virus, triggering an immune response to protect against Ebola infection.
As of recent updates, the Ebola V920 vaccine (also known as Ervebo) has been approved by regulatory authorities, including the FDA and EMA, for use in preventing Ebola virus disease.
The Ebola V920 vaccine is primarily intended for individuals at risk of Ebola virus infection, including healthcare workers, outbreak responders, and populations in areas with active Ebola outbreaks.
